Summary This study evaluates the effect of alendronate on osteoclastogenesis, cytokine production, and bone resorp- tion in postmenopausal women. We suggest that it acts on mature bone resorbing osteoclasts after 3 months of treatment, whereas, after 1 year, it diminishes their formation by reducing their precursors and serum RANKL. Introduction Osteoclasts are the target cells of bisphosph- onates, though the most drug-sensitive steps of their formation and activity have not been determined. The present study evaluates the effect of alendronate on osteoclastogenesis, cytokine production, and bone resorp- tion in postmenopausal women. Methods The study was conducted on 35 osteoporotic women; 15 were pretreated with alendronate 70 mg/week, whereas, 20 were treated with calcium 1 g/day and vitamin D 800 IU/day. After 3 months, 30 received alendonate 70/mg, vitamin D 2800 IU/week, and calcium 1 g/day for 12 months (combined therapy), whereas, the other five patients remained on calcium 1 g/day and vitamin D 800 IU/day. The following parameters were assessed before and after therapy: changes in bone resorption markers, circulating osteoclast precursors, formation of osteoclasts in peripheral blood mononuclear cell cultures, their viability, and variations in cytokines production. Results After 3 months of alendronate, there was no significant reduction in the number of osteoclast precursors, osteoclast formation and viability, and cytokine levels, whereas, there was a significant reduction of bone resorption markers. One year of the combined therapy, on the other hand, reduced osteoclast precursors, osteoclast formation, and serum RANKL, whereas, calcium plus vitamin D alone had no effect. Conclusions We suggest that alendronate mainly acts on mature bone resorbing osteoclasts in the short term, whereas, its long-term administration diminishes their formation by reducing their precursors and serum RANKL.

Alendronate reduces osteoclast precursors in osteoporosis

D'AMELIO, Patrizia;PESCARMONA, Gianpiero;ISAIA, Giovanni Carlo
2010

Abstract

Summary This study evaluates the effect of alendronate on osteoclastogenesis, cytokine production, and bone resorp- tion in postmenopausal women. We suggest that it acts on mature bone resorbing osteoclasts after 3 months of treatment, whereas, after 1 year, it diminishes their formation by reducing their precursors and serum RANKL. Introduction Osteoclasts are the target cells of bisphosph- onates, though the most drug-sensitive steps of their formation and activity have not been determined. The present study evaluates the effect of alendronate on osteoclastogenesis, cytokine production, and bone resorp- tion in postmenopausal women. Methods The study was conducted on 35 osteoporotic women; 15 were pretreated with alendronate 70 mg/week, whereas, 20 were treated with calcium 1 g/day and vitamin D 800 IU/day. After 3 months, 30 received alendonate 70/mg, vitamin D 2800 IU/week, and calcium 1 g/day for 12 months (combined therapy), whereas, the other five patients remained on calcium 1 g/day and vitamin D 800 IU/day. The following parameters were assessed before and after therapy: changes in bone resorption markers, circulating osteoclast precursors, formation of osteoclasts in peripheral blood mononuclear cell cultures, their viability, and variations in cytokines production. Results After 3 months of alendronate, there was no significant reduction in the number of osteoclast precursors, osteoclast formation and viability, and cytokine levels, whereas, there was a significant reduction of bone resorption markers. One year of the combined therapy, on the other hand, reduced osteoclast precursors, osteoclast formation, and serum RANKL, whereas, calcium plus vitamin D alone had no effect. Conclusions We suggest that alendronate mainly acts on mature bone resorbing osteoclasts in the short term, whereas, its long-term administration diminishes their formation by reducing their precursors and serum RANKL.
OSTEOPOROSIS INTERNATIONAL
21(10)
1741
1750
http://www.springerlink.com/content/454n457407454265/
Alendronate; Osteoclast; Osteoclast precursors; Osteoporosis; RANKL
P D’Amelio; A Grimaldi; MA Cristofaro; M Ravazzoli; PA Molinatti; GP Pescarmona; G Isaia
File in questo prodotto:
File Dimensione Formato  
Alendronate reduces osteoclast precursors in osteoporosis.pdf

non disponibili

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 337.09 kB
Formato Adobe PDF
337.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Alendronate reduces osteoclast precursors in osteoporosis.pdf

accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 767.2 kB
Formato Adobe PDF
767.2 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/72579
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 33
social impact